^
Association details:
Biomarker:TP53 mutation
Cancer:Prostate Cancer
Drug:abiraterone acetate (CYP17A1 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

Published date:
05/14/2021
Excerpt:
AR amplification and TP53 and/or RB1 alterations were associated with resistance to abiraterone or docetaxel.
DOI:
10.6004/jnccn.2020.7663
Evidence Level:
Resistant: C3 – Early Trials
Title:

Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.

Published date:
02/13/2020
Excerpt:
AR amplification and TP53 or RB1 defect were associated with resistance to abiraterone or docetaxel.
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.

Published date:
05/28/2020
Excerpt:
AR amplification and TP53 or RB1 defect were associated with resistance to abiraterone or docetaxel. CDK12 was more frequently altered in our cohort than those in previous reports which mainly focused on Caucasian population. The patients with CDK12 defect showed rapid resistance to abiraterone and limited efficacy of Poly (ADP-ribose) polymerase inhibitors (PARPi). However, these patients seemed to benefit from chemotherapy, especially platinum-based chemotherapy.
DOI:
10.1200/JCO.2020.38.15_suppl.e17556